Moderna's stock has reached a new 52-week high of $176.75 USD, trading at $176.21 USD with a market capitalization of $70.4 billion. This significant surge, reflecting a 510% one-year price total return and a 422% year-to-date increase, is attributed to advancements in its biotechnology sector, particularly its COVID-19 vaccine development. However, InvestingPro analysis advises caution due to high price volatility and expectations of unprofitability this year, suggesting the stock may be overvalued.

National Bank Financial has set a C$6.50 price target and an "outperform" rating for Denison Mines (TSE:DML), suggesting a potential 60.89% upside. This positive sentiment is echoed by other analysts, with a consensus "Buy" rating and an average target price of C$5.94. Despite reporting a quarterly loss of C$0.03 per share, Denison Mines' stock increased by 1.5% to C$4.04 on Monday.

CarMax has cut 145 white-collar jobs, approximately 4% of its corporate staff, marking its third round of layoffs in a year. This move by the nation's largest used-car retailer is part of a turnaround strategy under CEO Keith Barr to boost sales and profitability amidst high prices and rising interest rates in the auto market.

Rockwell Automation has joined Anthropic's Project Glasswing, a global initiative aimed at enhancing cybersecurity for critical industrial infrastructure through AI. By gaining controlled access to Claude Mythos 5, Rockwell's security teams will explore new methods to identify, validate, and remediate software vulnerabilities faster. This collaboration highlights Rockwell's commitment to secure-by-design innovation and strengthening the resilience of critical industrial operations against cyber threats.

Ciena (NYSE:CIEN) initially saw Wall Street analysts cut their price targets following its strong Q3 fiscal 2026 earnings report, despite record revenue and a large backlog, due to concerns over supply constraints. However, just two weeks later, many of these same firms raised their targets after Ciena presented ambitious fiscal 2029 targets at its investor forum, outlining significant revenue CAGR, adjusted gross margin, operating margin, and free cash flow margin. While bullish analysts see this as a strong multi-year framework for AI buildout, some bearish concerns remain regarding supply chain challenges and whether gross margins will truly reach the projected 50% target.

Louisville Mayor Craig Greenberg and university presidents are advocating for the city to evolve beyond its manufacturing roots and become a hub for innovation and design. The mayor wants companies like Ford and GE to not only build their products in Louisville but also to design and invent the next generation of products locally. This initiative aims to elevate Louisville's economic profile to a higher level of creative development.

Litmus, a provider of Industrial Data Platform for AI, has been recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for Global Industrial AIoT Platforms. The company's platform helps manufacturers standardize data pipelines across plants, making data ready for enterprise AI initiatives. Litmus also emphasizes its strategic partnerships with major technology vendors like Microsoft, Google Cloud, AWS, Databricks, and Snowflake, to bring governed factory data into analytics and AI services.

Meta's new AI personal agent tool, Muse, has quickly surpassed rivals like ChatGPT, Claude, and Grok in post-launch downloads, becoming the leading free iOS app in the U.S. within five days of its release. The app, powered by Meta's Muse Spark AI models, represents a significant push by Mark Zuckerberg into the AI agent market, offering services like form filling and email organization. Despite its rapid success and potential for new revenue streams through subscriptions, the launch comes amidst broader concerns about AI safety and privacy, with Amazon notably blocking the Muse bot from its site.

Moody's Ratings has upgraded Wayfair Inc.'s corporate family rating to B1 from B3, citing significantly improved credit metrics and robust sales and earnings growth. The upgrade also reflects Wayfair's strong market position, very good liquidity, and positive free cash flow. The outlook for Wayfair remains stable, with potential for further upgrades if debt to EBITDA is sustained below 4.5x and retained cash flow to net debt remains above 25%.

Medicus Pharma's stock dropped after its in-licensing deal with Pfizer for the CD228V antibody-drug conjugate (ADC), leading investors to fear dilution due to significant payments. However, author Mike Sheikh argues that the deal is a strategic move, transforming Medicus into an oncology platform technology with sublicensing rights and a de-risked asset from Pfizer's reprioritization after its Seagen acquisition. This acquisition, along with Medicus's experienced management and strategic financing, positions the company to efficiently develop CD228V and potentially monetize other pipeline assets like SkinJect and Teverelix through partnerships, rather than through a traditional "fire sale" acquisition.